Answers are grounded in this paper and cite their sources.
Findings show serum galectin-3 and GFAP levels predict injury severity and prognosis in spinal cord injury, indicating their potential as clinical indicators.
Serum Gal-3 and GFAP levels are significantly associated with injury severity at admission and 6-month prognosis in SCI patients. Serum Gal-3 and GFAP levels can be used as clinical risk factors for predicting SCI injury severity and 6-month prognosis.
No takes yet. Share an insight, caveat, or question.
Ou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: